Welcome to the World of Photocure ASA

A Closer Look at Hexvix®/Cysview® Revenue

OSLO, Norway , Feb. 19, 2025 /PRNewswire/ — Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA of NOK 8.5 million (NOK 29.9 million). Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025.

Photocure, a leading pharmaceutical company based in Norway, has recently announced its financial results for the fourth quarter of 2024. The company reported a significant increase in revenues for its flagship products Hexvix® and Cysview®, with a total of NOK 128.6 million generated in Q4 2024. This marks a considerable growth compared to the same period in 2023, where revenues amounted to NOK 114.2 million.

Despite the positive revenue growth, Photocure also reported a decline in EBITDA, with figures dropping to NOK 8.5 million in Q4 2024 from NOK 29.9 million in the previous year. However, the company remains optimistic about the future, forecasting a product revenue growth rate of 7% to 11% and expecting a year-over-year improvement in EBITDA for 2025.

The success of Hexvix® and Cysview® indicates the strong market position of Photocure in the field of pharmaceuticals, particularly in the development of innovative solutions for medical conditions. With a focus on growth and improvement, Photocure is poised to make significant advancements in the coming year.

How This Will Affect Me

As a consumer, the positive financial results of Photocure ASA indicate a commitment to innovation and growth in the pharmaceutical industry. This could lead to the development of more effective treatments and solutions for various medical conditions, ultimately benefiting patients like you and me.

How This Will Affect the World

The success of Photocure ASA and its flagship products Hexvix® and Cysview® have the potential to impact the global pharmaceutical market. With continued revenue growth and improvements in EBITDA, Photocure may contribute to the advancement of healthcare worldwide, leading to better treatment options for patients around the globe.

Conclusion

In conclusion, the recent financial results of Photocure ASA reflect a promising future for the company and the pharmaceutical industry as a whole. With a focus on growth, innovation, and improvement, Photocure is well-positioned to make a significant impact on healthcare and patient outcomes in the coming years.